To: HEALTH, MEDICAL AND NATIONAL EDITORS
Contact: CONTACT: Jane Woo, Fleishman-Hillard, +1-714-702-9499, jane.woo@fleishman.com; or Andrea Slesinski, ASH, +1-614-352-5096, aslesinski@hematology.org; or San Diego Convention Center (Dec. 10-13): +1-619-525-6228
SAN DIEGO, Dec.10, 2011 /PRNewswire-USNewswire/ -- Bleeding and clotting disorders impact a vast series of patients annually and, while accurate diagnosis is important, timely and effective diagnosis for these disorders is key, as they have a intensity to fast turn life-threatening. Research examining novel diagnosis techniques for draining and clotting disorders will be presented currently during a 53rd Annual Meeting of a American Society of Hematology.
Bleeding disorders, such as hemophilia B, are a organisation of conditions that outcome when a blood can't clot properly. In normal clotting, platelets (cells that means a blood to clot) hang together and form a retard during a site of an harmed blood vessel, permitting a harmed site to heal. Although a physique naturally dissolves blood clots after an repairs has totally healed, infrequently clots form on a inside of vessels though an apparent repairs or do not disintegrate naturally, heading to clotting disorders such as venous thromboembolism (VTE).
"In a United States alone, over half a million people a year rise inapt blood clots called thrombosis, and during slightest 100,000 people die any year from a pulmonary embolism. Because these clots can be so deadly, and can start unbeknownst to a patient, it is critical that we find new ways to diagnose and yield them," pronounced Charles Abrams, MD, judge of a press conference, 2011 ASH Secretary, and Professor of Medicine during a University of Pennsylvania School of Medicine in Philadelphia. "While draining disorders, such as hemophilia, are rebate common than clotting disorders, they can still be intensely dangerous. Results of these studies yield wish for intensity new treatments and denote a subsequent era of gene therapy to scold poor genes."
This press discussion will take place on Saturday, Dec 10, during 8:00 a.m. PST.
Aspirin After Oral Anticoagulants for Prevention of Recurrence in Patients with Unprovoked Venous Thromboembolism. The WARFASA Study [Abstract ]
A new investigate shows that administering aspirin after customary therapy for venous thromboembolism (VTE) might forestall a regularity of potentially lethal blood clots.
VTE is a that includes both deep-vein thrombosis and pulmonary embolism, that can lead to chest pain, fast pulse, crispness of breath, and, in impassioned cases, remarkable death. Patients who humour from VTE are given verbal anticoagulants, such as warfarin, to assistance forestall clot expansion and disintegrate existent clots or emboli (detached clots) in a veins. Other antithrombotic treatments embody antiplatelet agents, such as aspirin, that retard a arrangement of blood clots in a arteries by preventing platelets from clumping together and interference a blood upsurge to a heart or brain, that can means a heart conflict or stroke.
Recurrence of these lethal clots develops in 15 to 20 percent of patients who humour from VTE dual years after they finish required warfarin treatment. Although fluctuating anticoagulant diagnosis has been found to be effective in preventing recurrence, it is also compared with an increasing draining risk. The use of aspirin as an choice therapy to verbal anticoagulants has been argumentative since a drug is used to stop blood clots in a arteries and not veins. In addition, formula of prior studies that have assessed a ability to revoke regularity rates for VTE have been contradictory.
To consider a efficiency and reserve of aspirin for a impediment of VTE regularity after a required march of verbal anticoagulation therapy, researchers from several Italian institutions embarked on a randomized, double-blind, placebo-controlled WARFASA study. The organisation sought to establish either low-dose aspirin prevented memorable symptomatic VTE when given for dual years following an initial 6 to 12 months of warfarin therapy. Patients enrolled in a investigate with a initial unprovoked VTE (clot that occurs in a deficiency of famous risk factors, such as enlarged immobilization, surgery, or trauma), who had finished 6 to 12 months of verbal anticoagulant diagnosis were randomized to accept a daily sip of aspirin (205 patients) or remedy (197 patients) for during slightest dual years, with follow-up for adult to 36 months. The primary efficiency outcome was objectively reliable memorable symptomatic VTE and VTE-related death. Clinically applicable (major and non-major) draining were a categorical reserve outcomes.
VTE regularity was celebrated in 28 of a 205 patients who perceived aspirin and 43 of a 197 patients who perceived remedy (6.6% vs. 11.2% per patient-year, respectively). While on investigate treatment, 23 patients who perceived aspirin and 39 patients who perceived remedy gifted VTE regularity (5.9% vs. 11.0 % per patient-year, respectively). Major draining occurred in one studious in any diagnosis group, with a identical occurrence of clinically applicable non-major bleeding.
"There has been poignant discuss on either giving aspirin to a studious who suffers from VTE is beneficial," pronounced lead investigate author Cecilia Becattini, MD, Assistant Professor of Internal Medicine in a Internal and Cardiovascular Medicine and Stroke Unit during a University of Perugia in Italy. "Our investigate shows that aspirin, a common and low-cost drug found in many medicine cabinets, can be a current choice to verbal anticoagulants for a extended diagnosis of VTE."
Dr. Becattini will benefaction this investigate in an verbal display on Monday, Dec 12, during 3:15 p.m. PST during a San Diego Marriott Marquis & Marina in Hall 4.
Platelet Production System Using an Immortalized Megakaryocyte Cell Line Derived From Human Pluripotent Stem Cells [Abstract ]
Researchers are one step closer to building organic tellurian platelets from prompted pluripotent branch (iPS) cells that can be used in humans after formulating them in vitro and proof their functionality in a rodent model.
"There is a ongoing necessity of donated platelets in blood banks, since distinct other tools of a blood, platelets can't be solidified and stored for an extended duration of time," pronounced Sou Nakamura, lead author of a investigate and Research Associate during a Center for iPS Cell Research and Application (CiRA) during Kyoto University in Japan. Human iPS cells are a earnest source of blood cells, including platelets; however, a categorical rebate until now has been a ability to find a process that creates a vast series of high-quality, organic platelets.
To residence these limitations, investigators from CiRA and a Center for Stem Cell Biology and Regenerative Medicine during a University of Tokyo set out to emanate an immortalized dungeon line with a vast series of high-quality megakaryocytes (precursor cells that rise into platelets) from tellurian rudimentary branch cells or iPS cells that can be grown indefinitely and compute into a accumulation of dungeon forms in a body. Immortalized dungeon lines offer a probability of a renewable supply of cells that can be used as models of animal or tellurian tissue.
Previously, a investigate organisation had demonstrated that rise activation of c-MYC (a gene that is essential for a proliferation of tellurian cells) in megakaryocyte progenitor cells, followed by a rebate of c-MYC expression, are pivotal components of in vitro platelet generation. The organisation also found that a overexpression of c-MYC not customarily increasing a series of megakaryocytes, though also prompted apoptosis (cell death) and dungeon senescence (when cells can no longer order and reproduce).
In this study, investigators combined an immortalized megakaryocyte dungeon line by overexpressing c-MYC and a BMI1 gene (a polycomb gene essential for a impediment of senescence), that afterwards generated organic platelets in vivo once a overexpression of those genes was incited off. The researchers serve tested a functionality of a well-bred platelets by infusing them into immunodeficient rodent models and reliable that they had a same life camber as normal tellurian platelets infused in mice.
"This is an sparkling growth for a transfusion community, as a methodology has proven that platelets can be combined in a lab from tellurian iPS cells," pronounced comparison author Koji Eto, MD, PhD, Professor during CiRA. "The subsequent step will be to control a hearing to establish either a platelets can duty in a tellurian physique and potentially yield a fast supply of platelets during a predefined peculiarity and apportion that can afterwards be used for transfusion therapy."
Naoya Takayama, MD, PhD, will benefaction this investigate during a Plenary Scientific Session on Sunday, Dec 11, during 2:25 p.m. PST during a San Diego Convention Center in Hall AB.
Adeno-Associated Viral Vector Mediated Gene Transfer for Hemophilia B [Abstract ]
Researchers have successfully tested a intensity heal for critical hemophilia B in 6 patients regulating gene therapy.
Hemophilia B is a genetic draining commotion caused by poor or blank recombinant means IX (FIX). Insufficient amounts of this protein prevents blood from clotting routinely and can outcome in enlarged draining after repairs or surgery, or extemporaneous draining in a deficiency of trauma. This draining can means permanent repairs to joints, muscles, and other tools of a body, including a brain.
"While all patients who humour from hemophilia B customarily need deputy therapy, or distillate of recombinant FIX protein to reinstate a poor clotting means after an part of trauma, patients with a critical form of a commotion customarily have to bear revisit infusions, customarily twice a week, to forestall extemporaneous draining episodes," pronounced comparison author Andrew M. Davidoff, MD, Chairman of a Department of Surgery during St. Jude Children's Research Hospital in Memphis, Tenn. "Our ongoing investigate has been examining a use of gene therapy as a diagnosis proceed for hemophilia B to soothe a weight of revisit infusions on these patients."
The plan uses a gene send approach, that replaces a poor gene that causes a commotion with a scold chronicle in a patient's liver cells, a normal site of FIX synthesis, so that patients can make their possess FIX. Work on a matrix was instituted during St. Jude some-more than a decade ago by Dr. Davidoff and Amit Nathwani, MD, PhD, co-lead investigate author, of a Department of Hematology during UCL Cancer Institute in London, United Kingdom, underneath a stewardship of Arthur W. Nienhuis, MD, also a co-author of a investigate and a member of a St. Jude Hematology department. Since a work was initiated, several other scientists and educational institutions have contributed to a formidable general investigate effort.
A display during a 2010 ASH Meeting suggested rough formula of a study, that evaluated dual sip levels of a viral matrix that enabled a send of a normal gene for FIX sufficient to beget healing levels of a protein though causing inauspicious effects in 4 patients. Since then, investigators have administered a matrix in dual additional patients with critical hemophilia B during a aloft sip and have now followed a whole conspirator 6 to 16 months post treatment.
The 6 hearing participants were given an distillate that contained a matrix carrying a normal duplicate of a FIX gene around a capillary in a arm. Two subjects were treated with a low dose, dual with an middle dose, and dual with a high sip of a vector. Vector-mediated levels of FIX rose from rebate than 1 percent of normal before therapy to between 2 percent and 12 percent of normal levels in all 6 patients. The FIX levels, in a initial theme who has been followed for a longest time, have remained during 2 percent for some-more than 12 months following gene transfer. The top turn of FIX countenance has been celebrated in a dual subjects treated during a top sip level, with countenance trimming from 3 percent to 12 percent. Four of a 6 participants have dropped preventative diagnosis and sojourn giveaway of extemporaneous bleeding, and a remaining dual patients have increasing a time interlude between FIX infusions.
"We have grown a matrix for gene send that is some-more fit and effective than normal diagnosis for patients with critical hemophilia B by preventing extemporaneous draining in this high-risk studious population," pronounced Dr. Nathwani. "Our novel proceed shows guarantee for softened gene therapy of hemophilia B and other protein deficiencies."
Dr. Nathwani will benefaction this investigate during a Plenary Scientific Session on Sunday, Dec 11, during 3:25 p.m. PST during a San Diego Convention Center in Hall AB.
Improved Functional Outcome After Additional Catheter-Directed Thrombolysis for Acute Iliofemoral Deep Vein Thrombosis: Results of a Randomized Controlled Clinical Trial (The CaVenT Study) []
In a largest randomized investigate achieved to date, researchers have found that additional diagnosis with catheter-directed thrombolysis (CDT), when compared to customary diagnosis of verbal anticoagulation therapy and effervescent application stockings (ECS), reduces a risk of post-thrombotic syndrome (PTS) in patients who humour from deep-vein thrombosis (DVT) in their revoke limbs.
PTS, a ongoing snarl of DVT that causes swelling, pain, cramping, and venous ulcers, occurs in approximately one in 4 patients who humour from lower-limb DVT treated with customary therapy.
To revoke a risk of building PTS, additional therapy is indispensable around catheter-directed thrombolysis (CDT), a minimally invasive procession that uses cat-scan imaging to discharge remedy to assistance disintegrate clots by a catheter placed in a vein. CDT has turn customary of caring for a impediment of PTS in some diagnosis centers, notwithstanding a miss of randomized, tranquil trials demonstrating a efficiency and safety, as good as several drawbacks including a high expense, organisation with life-threatening bleeding, and bent to modify DVT (typically an outpatient condition) to an in-patient illness requiring hospitalization.
To weigh either additional diagnosis of DVT with CDT with alteplase (a clot-dissolving medication) reduces PTS growth following strident iliofemoral DVT (occurring in a top thigh and/or pelvic area), researchers embarked on a Catheter-Directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis (CaVenT) study, a large, four-year, multicenter, randomized tranquil trial.
In this trial, 209 patients between a ages of 18 and 75 with a first-time strident iliofemoral DVT, with symptoms benefaction for adult to 21 days, were randomized into dual diagnosis arms: Treatment arm A (the CDT-treated arm) had 101 patients and arm B (control arm treated with verbal anticoagulant and ECS) had 108 patients. The primary endpoint of a hearing was a magnitude of PTS after 24 months of follow-up.
Of a 90 CDT-treated patients and 99 control patients who had information accessible for analysis, 41.1 percent of patients treated with CDT presented symptoms of PTS compared to 55.6 percent of control patients. The disproportion in PTS occurrence corresponds to an comprehensive risk rebate of 14.4 percent in patients treated with CDT.
Twenty draining complications were reported, 3 personal as vital and 5 deliberate clinically relevant. None of a reported draining episodes caused critical complications, and there were no pulmonary emboli, strokes, or deaths associated to diagnosis with CDT. After 6 months of follow-up, PTS grown in 36.9 percent of patients who no longer had a clotted vein, as compared to 61.3 percent of patients who still gifted clotting. These outcomes underscore a significance of recanalization, a unblocking of a blood vessel, for preventing PTS and ensuring certain outcomes in patients with DVT.
"The formula of a hearing uncover that additional diagnosis with CDT significantly reduces a risk of PTS in patients with DVT, compared to customary diagnosis alone," pronounced Per Morten Sandset, MD, PhD, comparison author and Head of Research, Clinic of Cancer, Surgery, and Transplantation during Oslo University Hospital in Norway. "Although CDT is a earnest diagnosis choice for patients with iliofemoral DVT, a therapy also increases a risk of bleeding, emphasizing a significance of studious preference and reserve when behaving CDT procedures. Our commentary advise that CDT should be deliberate in patients with top thigh or pelvic DVT."
Dr. Tone Ronnaug Enden will benefaction this investigate during a Late-Breaking Abstracts Session on Tuesday, Dec 13, during 7:30a.m. PST during a San Diego Convention Center in Hall AB.
American Society of Hematology 53rd Annual Meeting
The investigate authors and press module judge will be accessible for interviews after a press discussion or by telephone. Additional press briefings will take place via a assembly on targeted therapies for strident and ongoing leukemia, improving liberation and outcomes in transplantation, rising treatments for lymphoma and myeloma, and assessing healing strategies for sickle dungeon disease. For a finish annual assembly module and abstracts, revisit . Get present information about a annual assembly by following ASH on Twitter .
The American Society of Hematology (www.hematology.org) is a world's largest veteran multitude endangered with a causes and diagnosis of blood disorders. Its goal is to serve a understanding, diagnosis, treatment, and impediment of disorders inspiring blood, bone marrow, and a immunologic, hemostatic, and vascular systems by compelling research, clinical care, education, training, and advocacy in hematology. The central biography of ASH is Blood (www.bloodjournal.org), a many cited peer-reviewed announcement in a field, that is accessible weekly in imitation and online.
SOURCE American Society of Hematology
-0-
News referensi http://news.yahoo.com/studies-examine-novel-treatment-techniques-bleeding-clotting-disorders-160110654.html
0 comments:
Post a Comment